NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Lifordi Immunotherapeutics, Inc.

Lifordi Immunotherapeutics, Inc.

Private
Burlington, MassachusettsHealthcare & Life Scienceshttps://www.lifordi.com/

Last Round

Series A

Extension

Nov 18, 2025

Total Funding Raised

$112M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Lifordi Immunotherapeutics, Inc. is a biotechnology company that develops targeted antibody-drug conjugates (ADCs) for the treatment of autoimmune and inflammatory disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

antibody-drug conjugateADCtargeted drug deliveryautoimmune diseasebiotechnologydrug discoverybiotechinflammatory disordersprecision medicineclinical-stage biotechdrug licensingbiopharmarheumatoid arthritistherapeutic payload

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Lifordi Immunotherapeutics, Inc. Comparables

Compare Lifordi Immunotherapeutics, Inc. with similar companies based on industry and business-model similarity.

Lifordi Immunotherapeutics, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Santa Ana Bio
79%
AbbVie
76%
AbolerIS Pharma
71%

Lifordi Immunotherapeutics, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionNov 18, 2025

Key People

Founding team and executive leadership

Arthur Tzianabos

Chief Executive Officer

Executive Team

Lifordi Immunotherapeutics, Inc. Investors

Notable investors and investment history

Lifordi Immunotherapeutics, Inc. investors
InvestorRounds
ARCH Venture PartnersSeries A, Series A Extension
5AM VenturesSeries A, Series A Extension
Sanofi VenturesSeries A Extension
Atlas VentureSeries A, Series A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 1, 2026

    Monthly visitors increased 59% MoM, reaching 12.4K.

  • Jan 24, 2026

    Monthly visitors increased 1486% MoM, reaching 7.8K.

Lifordi Immunotherapeutics, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Lifordi Immunotherapeutics, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Lifordi Immunotherapeutics, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersBurlington, Massachusetts
Employee Range23
Year Founded2023
Last FundingNov 18, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.